A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors

This study is testing an experimental oncolytic virus injection called R130 OV — a virus engineered to infect and destroy cancer cells — directly into tumors in patients with advanced solid cancers that have not responded to standard treatments. This is a Phase I safety and dose-finding trial. **You may be eligible if...** - You are 18 to 75 years old with a confirmed advanced solid tumor that failed standard treatment - You have at least one tumor that can be directly injected - Your overall health is acceptable (ECOG 0–2) and organ function meets required levels **You may NOT be eligible if...** - You had a serious reaction to prior immunotherapy - You have uncontrolled high blood pressure, serious heart conditions, active severe infection, or prior organ transplant - You have Type 1 diabetes, HIV, or active tuberculosis - You have active bleeding or severe clotting problems - You had anticancer therapy within 4 weeks of starting this study - You are pregnant, breastfeeding, or planning a pregnancy within 6 months Talk to your doctor to see if this trial is right for you.